Renalys Pharma's sparsentan receives Japanese Orphan Drug Designation for primary IgA nephropathy
Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. (Travere) and currently in phase III clinical trials in Japan, has received Orphan Drug Designation from the …